BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
Portfolio Pulse from Lara Goldstein
BetterLife Pharma Inc. (OTCQB:BETRF) is fast-tracking its U.S. patent application for non-hallucinogenic LSD derivatives, including its 2-bromo-LSD derivative BETR-001, which is expected to begin clinical trials for Major Depressive Disorder. The patent covers the composition, treatment uses, and a novel production method. The company's CEO, Dr. Ahmad Doroudian, highlighted the compound's neuroplasticity properties and efficacy in preclinical models of depression, anxiety, and pain. Another biotech company, PharmaTher Holdings (OTC:PHRRF), recently fast-tracked an application for its proprietary racemic ketamine, KETARX, for the treatment of levodopa-induced dyskinesia in Parkinson’s disease.
June 28, 2023 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BetterLife Pharma is fast-tracking its U.S. patent for non-hallucinogenic LSD derivatives, which could potentially lead to new treatments for neuropsychiatric and neurological conditions.
The fast-tracking of the patent application indicates the company's confidence in the potential of its LSD derivatives. If the patent is granted and the clinical trials are successful, it could lead to new revenue streams for the company, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
PharmaTher Holdings recently fast-tracked an application for its proprietary racemic ketamine, KETARX, for the treatment of levodopa-induced dyskinesia in Parkinson’s disease.
The fast-tracking of the application for KETARX indicates the company's confidence in the potential of this treatment. If the application is successful, it could lead to new revenue streams for the company, positively impacting its stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50